Padernal, Michelle .

HRN: 27-13-68  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/21/2025
CO-AMOXICLAV 625MG (TAB)
05/21/2025
05/28/2025
ORAL
625mg
BID
S/P NSD; PROM
Waiting Final Action 

Indication:  Prophylaxis    Type of Infection:  Reproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: